Ajanta Pharma Inks In-Licensing Deal with Biocon for Semaglutide
Filing Summary
Ajanta Pharma Ltd. has entered into an in-licensing agreement with Biocon Ltd. for the marketing of Semaglutide, a GLP-1 receptor agonist, in 26 countries across Africa, the Middle East, and Central Asia. The agreement grants Ajanta exclusive marketing rights in 23 countries and semi-exclusive rights in 3 countries. The product patent expires in March 2026, with commercialization planned post-regulatory approvals anticipated in late 2026 or early 2027. Ajanta reported revenue of Rs. 4,648 crore for FY 2024-25, with a PAT of Rs. 920 crore.
Ajanta Pharma Ltd. has announced an in-licensing agreement with Biocon Ltd. for the marketing of Semaglutide, a GLP-1 receptor agonist, in 26 countries. The agreement allows Ajanta exclusive marketing rights in 23 countries and semi-exclusive rights in 3 countries across Africa, the Middle East, and Central Asia. Semaglutide is used to improve glycaemic control in adults, and its product patent is set to expire in most of these markets by March 2026.
For the fiscal year 2024-25, Ajanta Pharma reported a revenue of Rs. 4,648 crore, an EBIDTA of Rs. 1,260 crore, and a PAT of Rs. 920 crore. The company has achieved a revenue CAGR of 11% and a PAT CAGR of 25% over the last three financial years. These figures reflect Ajanta’s financial performance and growth trajectory in its operational markets.
The scope of the agreement involves Biocon supplying Semaglutide to Ajanta, which will handle the marketing in the specified regions. Ajanta plans to commercialize the product following the receipt of regulatory approvals, expected in late 2026 or early 2027. Ajanta has a robust presence in over 30 countries, focusing on therapeutic segments such as Cardiology, Antidiabetic, Ophthalmology, and others. The company has more than 220 brands in emerging markets, supported by over 2,000 medical representatives.
Ajanta Pharma has been a pioneer in building a strong branded generic business in its operational regions. The company has expanded its product portfolio and field size, establishing leadership positions across several therapeutic segments. Ajanta’s strategy involves identifying market gaps, obtaining regulatory approvals, and launching differentiated products to build sustainable brands.
The timeline for the commercialization of Semaglutide is contingent upon regulatory approvals, which are anticipated in late 2026 or early 2027. The agreement with Biocon marks a strategic move for Ajanta to enhance its product offerings in the diabetes care segment across its operational regions.
Biocon Ltd. is an innovation-led global biopharmaceutical company focused on enhancing affordable access to complex therapies for chronic conditions. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and key global markets. Biocon’s collaboration with Ajanta aims to expand its GLP-1 portfolio’s global footprint.
Ajanta Pharma Ltd. is a specialty pharmaceutical formulation company with a major focus on branded generic business across India, Asia, and Africa. The company operates in over 30 countries, offering a wide range of therapeutic products. Ajanta has a state-of-the-art R&D center and seven manufacturing facilities in India, supporting its strategic focus on expanding its product portfolio and market presence.